Meet us at the MEDICA trade fair in Düsseldorf, 11–14 November!

Logo TauroLock Logo TauroPharm

Lock solutions in parenteral nutrition

Ingredients, efficacy, recommendations

There are many reasons why patients might become dependent on partial or total parenteral nutrition (PPN/TPN): 

  • short bowel syndrome
  • malfunctions of the GI (gastro-intestinal) tract
  • critical diseases
  • and others

This can affect elderly people as much as young adults, children, and even infants. Nutrients must then be administered through a central-venous catheter (CVC) implanted in the patient’s chest. While CVC systems can save lives, they also bear considerable risks. Therefore, we have developed specialised lock solutions to protect patients against catheter-related complications and infections. 

TauroLock™ for patients in need of parenteral nutrition

Vascular access devices (VAD) such as catheters can quickly turn into a breeding ground for germs. This poses a particular threat to people who already suffer from other medical problems: In fact, catheter-related infections are a common cause of death among TPN patients? (Sun et al. PLoS ONE 2020. DOI: 10.1371/journal.pone.0231110.) TauroLock™ lock solutions are designed to make the process of parenteral nutrition as safe and convenient as possible. All of our products contain one main ingredient:

The antimicrobial agent taurolidine kills more than 500 types of germs. 

Apart from infections, patients must also avoid occlusions. Contact with blood, especially at the tip of the catheter, can lead to severe blood clotting. We offer lock solutions with anticoagulant or fibrinolytic substances to maintain an adequate flow rate: citrate, heparin, and/or urokinase. 

TauroLock™ in parenteral nutrition

In addition to taurolidine, TauroLock™ contains 4 % citrate. This formula prevents the development of an infective biofilm and occlusions in the catheter: the lock solution has an antiseptic and anti-occlusive effect.

NutriLock™ in parenteral nutrition

With some patients, citrate can lead to hypocalcemia (i.e. lower calcium levels). Possible symptoms include temporary sensations of tingling fingers and a metallic taste. For patients – especially young children – who want to avoid those side effects, we recommend using NutriLock™. This lock solution is citrate-free, but has the same bactericidal and fungicidal efficacy as TauroLock™. 

 

TauroLock™-Hep100 in parenteral nutrition

In addition to taurolidine and 4 % citrate, TauroLock™ -HEP100 contains 100 IU of heparin per ml. Heparin is an anticoagulant and helps to prevent occlusions that might also occur at the tip of central-venous catheters. Patients can use this lock solution to avoid infections and improve the flow rate. 

TauroLock™-U25.000 in parenteral nutrition

As a third alternative, we offer a lock solution with taurolidine, 4 % citrate, and 25,000 IU of the thrombolytic agent urokinase. TauroLock™-U25.000 ensures a high patency rate and strong protection against catheter-related infections. 

 

All ingredients named above have been approved and recommended in current guidelines (GPOH,  ESPEN, GaVeCeLT, DGE, and other national guidelines).

Please note that all TauroLock™ products are to be administered by trained staff with medical expertise and experience. On this premise, we advise the following procedure:

1. Before parenteral nutrition

  • Remove TauroLock™/NutriLock™/TauroLock™-Hep100/TauroLock™-U25.000 and residual blood from the VAD.
  • Once the VAD no longer contains any lock solution, flush all lumens with 10 ml of saline and a syringe according to the push-pause technique.
  • Start parenteral nutrition.

 

2. After parenteral nutrition

  • Flush both lumens with 10 ml of saline according to the push-pause technique.
  • Gently tap the ampoule’s neck to remove the lock solution.
  • Tilt the ampoule so that you can see a white dot on top and quickly break off the neck.
  • When using TauroLock™-U25.000:Reconstitute the urokinase that is delivered in a separate vial with TauroLock™ withdrawn from the ampoule. TauroLock™-U25.000 must be used immediately after reconstitution.
  • Draw the TauroLock™ solution from the ampoule into a sterile syringe.

 

3. In-between treatment sessions

  • To ensure the solution’s prophylactic efficacy, slowly instil a volume sufficient to fill the entire lumens of the device.
  • You can check the proper filling volume of each lumen as indicated on the device or based on the manufacturer’s instructions.  

More information

Download materials on lock solutions in parenteral nutrition

TauroPharm

Newsletter

We'll keep you posted on upcoming events, free download materials, and research insights.

Our website uses cookies and Analytics to guarantee you the best possible user experience. You can find more information in our privacy policy.